SciSparc’s subsidiary NeuroThera Labs Initiates Phase IIb Clinical Trial Site At Hannover Medical School In Germany For SCI-110, Proprietary Cannabinoid-Based Treatment Candidate For Tourette Syndrome In Adults

Loading news article.

SciSparc’s subsidiary NeuroThera Labs Initiates Phase IIb Clinical Trial Site At Hannover Medical School In Germany For SCI-110, Proprietary Cannabinoid-Based Treatment Candidate For Tourette Syndrome In Adults | WAPE

SciSparc’s subsidiary NeuroThera Labs Initiates Phase IIb Clinical Trial Site At Hannover Medical School In Germany For SCI-110, Proprietary Cannabinoid-Based Treatment Candidate For Tourette Syndrome In Adults

Article summary

Related companies

Comments —